From: Pharmacogenetic heterogeneity of transgene expression in muscle and tumours
A | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
---|---|---|---|---|---|---|---|---|---|---|
Infectibility (% Ad in cell / Ad seeded) | ||||||||||
MOI | Cell lines | |||||||||
 | U251 | NCI H460 | HepG2 | A549 | LS 174T | |||||
1 | 72 | 82 | 13 | 15 | 12 | 14 | 34 | 38 | 0.9 | 1 |
10 | 55 | 104 | 7 | 13 | 10 | 18 | 21 | 40 | 0.5 | 1 |
100 | 78 | 101 | 10 | 13 | 9 | 12 | 22 | 29 | 0.8 | 1 |
Average | Â | 96 | Â | 14 | Â | 15 | Â | 36 | Â | 1 |
SD | Â | 12 | Â | 1 | Â | 3 | Â | 6 | Â | Â |
B | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Transcription efficiency (mRNA / Ad DNA | ||||||||||
MOI | Cell lines | |||||||||
 | U251 | NCI H460 | HepG2 | A549 | LS 174T | |||||
1 | 2.1 | 0.7 | 2.1 | 0.8 | 2.0 | 0.7 | 0.4 | 0.14 | 2.8 | 1 |
10 | 2.0 | 0.7 | 2.7 | 0.9 | 1.9 | 0.7 | 0.4 | 0.16 | 2.8 | 1 |
100 | 1.9 | 0.7 | 2.7 | 1.0 | 2.3 | 0.9 | 0.6 | 0.22 | 2.6 | 1 |
Average | Â | 0.72 | Â | 0.91 | Â | 0.76 | Â | 0.17 | Â | 1 |
SD | Â | 0.02 | Â | 0.14 | Â | 0.11 | Â | 0.04 | Â | Â |
C | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Translation efficiency (Luciferase / mRNA) | ||||||||||
MOI | Cell lines | |||||||||
 | U251 | NCI H460 | HepG2 | A549 | LS 174T | |||||
1 | 40 | 2.8 | 12 | 0.8 | 13 | 0.9 | 9 | 0.6 | 14 | 1 |
10 | 127 | 2.2 | 48 | 0.8 | 38 | 0.7 | 28 | 0.5 | 58 | 1 |
100 | 316 | 1.6 | 152 | 0.8 | 140 | 0.7 | 78 | 0.4 | 198 | 1 |
Average | Â | 2.2 | Â | 0.8 | Â | 0.8 | Â | 0.5 | Â | 1 |
SD | Â | 0.6 | Â | 0.04 | Â | 0.2 | Â | 0.1 | Â | Â |
D | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Luciferase activity | ||||||||||
MOI | Cell lines | |||||||||
 | U251 | NCI H460 | HepG2 | A549 | LS 174T | |||||
1 | 60 | 172 | 3 | 9.2 | 3 | 9.5 | 1 | 3.4 | 0.3 | 1 |
10 | 1381 | 158 | 92 | 10.5 | 69 | 7.9 | 27 | 3.1 | 9 | 1 |
100 | 46350 | 116 | 4061 | 10.1 | 3055 | 7.6 | 1016 | 2.5 | 400 | 1 |
Average | Â | 149 | Â | 9.9 | Â | 8.3 | Â | 3.0 | Â | 1 |
SD | Â | 29 | Â | 0.7 | Â | 1.0 | Â | 0.4 | Â | Â |